Sonographic diagnosis of fetal malformations associated with mycophenolate mofetil exposure in utero

Area of Science:

• Reproductive toxicology
• Immunosuppressive therapy
• Teratology

Background:

• Mycophenolate mofetil is an immunosuppressant medication used in autoimmune diseases like systemic lupus erythematosus.
• Preclinical studies and existing reports suggest mycophenolate mofetil possesses teratogenic properties.

Observation:

• A 36-year-old patient with systemic lupus erythematosus was exposed to mycophenolate mofetil in utero.
• Diagnosis of major fetal malformation was established via ultrasonography at 22 weeks of gestation.

Findings:

• The observed major fetal malformation is strongly suspected to be a consequence of in utero mycophenolate mofetil exposure.
• This case adds to the clinical evidence of mycophenolate mofetil's teratogenic potential.

Implications:

• Clinicians should exercise caution when prescribing mycophenolate mofetil to women of childbearing potential, especially those with systemic lupus erythematosus.
• Enhanced awareness and counseling regarding fetal risks are crucial for patients on mycophenolate mofetil therapy.
• Further research into safer alternatives or risk mitigation strategies for pregnant patients is warranted.